← Back to Search

Anakinra for CAR-T Cell Therapy Side Effects in Lymphoma

Phase 2
Waitlist Available
Led By Jae Park, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients (age >/= 18) with a diagnosis of relapsed CD19+ B-cell ALL, MCL, or NHL receiving commercially approved CD19-specific CAR T cells (e.g. tisagenleuleucel, axicabtagene, brexucabtagene autoleucel, etc) are eligible for the study
Be older than 18 years old
Must not have
Women who are pregnant or breastfeeding
Patients with uncontrolled systemic fungal and bacterial infections
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days from the start of treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if anakinra can prevent or reverse the severe side effects of CAR-T cell therapy.

Who is the study for?
This trial is for adults over 18 with relapsed B-cell ALL, MCL, or NHL who are getting approved CD19-specific CAR T cell therapy. It's not for pregnant or breastfeeding women, those with uncontrolled infections, or anyone allergic to E. coli-derived proteins.
What is being tested?
The study tests if anakinra can prevent or treat severe side effects in patients undergoing CAR-T cell therapy for certain blood cancers like lymphomas and leukemia.
What are the potential side effects?
Anakinra may cause reactions at the injection site, headache, nausea, diarrhea, joint pain and swelling. There might also be a risk of infection due to its effect on the immune system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 or older with relapsed B-cell cancer and will receive approved CAR T cell therapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
I do not have any uncontrolled fungal or bacterial infections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days from the start of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days from the start of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities
Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation

Side effects data

From 2018 Phase 2 & 3 trial • 104 Patients • NCT01809132
19%
Acute Kidney Injury
11%
Ascites
9%
Nausea
9%
Urinary tract infection
8%
Hematemesis
8%
Upper GI hemorrhage
8%
Clostridium difficile infection
6%
Hepatic failure
6%
Encephalopathy
6%
C. difficile infection
4%
Respiratory Failure
4%
Peritonitis
4%
Esophageal varices hemorrhage
4%
Tachycardia
4%
Multiple Organ Dysfunction Syndrome (MODS)
2%
Viremia
2%
Baceteremia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Anakinra & Pentoxifylline & Zinc Sulfate
Methylprednisolone
Observational

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm 1 (CART Cell Group)Experimental Treatment1 Intervention
Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days. Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Anakinra
2016
Completed Phase 4
~1320

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
600,016 Total Patients Enrolled
Jae Park, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
15 Previous Clinical Trials
509 Total Patients Enrolled

Media Library

Anakinra Clinical Trial Eligibility Overview. Trial Name: NCT04148430 — Phase 2
B-Cell Lymphoma Research Study Groups: Arm 1 (CART Cell Group)
B-Cell Lymphoma Clinical Trial 2023: Anakinra Highlights & Side Effects. Trial Name: NCT04148430 — Phase 2
Anakinra 2023 Treatment Timeline for Medical Study. Trial Name: NCT04148430 — Phase 2
~8 spots leftby Oct 2025